Our site is slower due to heavy traffic from automated ’bots’ and AI crawlers. We’re working to fix this. Read more here.

Paula Cannon, PhD

Title(s)Distinguished Professor of Molecular Microbiology & Immunology, Stem Cell Biology & Regenerative Medicine and Biomedical Engineering
SchoolKeck School of Medicine of Usc
AddressHMR 413A 2011 Zonal Avenue
Health Sciences Campus
Los Angeles CA 90089
Phone+1 323 442 1510
vCardDownload vCard
    Other Positions
    Title(s)Associate Director of Cross School Programs for the MESH Academy

    Title(s)Special Advisor to the Provost


    Collapse Overview 
    Collapse overview
    Cannon Lab Website: http://uscmmi.com/paulacannonlab

    Paula Cannon, PhD, is a Distinguished Professor of Molecular Microbiology and Immunology in the Keck School of Medicine of USC, with a joint appointment in the Viterbi School of Engineering. She obtained her PhD from the University of Liverpool in the UK and did postdoctoral work on HIV and gene therapy at Harvard and Oxford Universities. Dr. Cannon uses gene editing technologies such as CRISPR/Cas9 to engineer immune cells, with the goal of developing treatments for HIV, cancer and other chronic diseases. Most recently, her lab has focused on engineering B cells to express custom therapeutic molecules, including antibodies that are not easily generated naturally by vaccination, but could suppress chronic infections such as HIV.

    Dr. Cannon is the current president (2025) of the American Society of Gene and Cell Therapy.

    Collapse Research 
    Collapse research activities and funding
    Nuclear receptor regulation of epigenetic mechanisms regulating HIV CNS latency
    NIH R01MH134316Aug 1, 2023 - May 31, 2028
    Role: Co-Investigator
    Gene edited B cells to co-express CNS-targeted antibodies
    NIH R21MH130178Apr 1, 2022 - Mar 31, 2024
    Role: Principal Investigator
    In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies
    NIH R01AI167003Dec 3, 2021 - Nov 30, 2026
    Role: Co-Investigator
    Reversing Immune Dysfunction for HIV-1 Eradication
    NIH UM1AI164561Aug 16, 2021 - Apr 30, 2026
    Role: Co-Principal Investigator
    Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure
    NIH U19HL156247May 15, 2020 - Apr 30, 2025
    Role: Principal Investigator
    Targeted inactivation of HIV in CNS reservoirs
    NIH R01MH113457Apr 20, 2017 - Jan 31, 2022
    Role: Principal Investigator
    Next Generation HSC Gene Therapy for HIV Control and Eradication
    NIH U19HL129902Apr 1, 2015 - Mar 31, 2021
    Role: Principal Investigator
    HIV-specific nucleases to reservoir cells
    NIH R33AI110149Nov 21, 2013 - Feb 29, 2020
    Role: Principal Investigator
    HIV-specific nucleases to reservoir cells
    NIH R21AI110149Nov 21, 2013 - Feb 29, 2016
    Role: Principal Investigator
    Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release
    NIH R01AI068546Apr 1, 2006 - Mar 31, 2012
    Role: Principal Investigator
    Retroviral Vectors for Safe and Efficacious Gene Therapy
    NIH R42RR019834Jun 1, 2004 - Dec 30, 2009
    Role: Principal Investigator
    Retroviral Vectors for Safe and Efficacious Gene Therapy
    NIH R41RR019834Jun 1, 2004 - Nov 30, 2005
    Role: Principal Investigator
    ENTRY PATHWAY OF NEW WORLD CLADE B ARENAVIRUSES
    NIH R21AI055720Sep 1, 2003 - Aug 31, 2006
    Role: Principal Investigator

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Engineering B cells to Express Fully Customizable Antibodies with Enhanced Fc Functions. Res Sq. 2025 Sep 09. Huang C, Mathur A, Chang CH, Huang X, Chen HY, Davis ZB, O'Dell K, Shuman EA, Kung RW, Rogers GL, Cannon PM. PMID: 40964038; PMCID: PMC12440107.
      View in: PubMed   Mentions:
    2. Engineering B cells to Express Fully Customizable Antibodies with Enhanced Fc Functions. bioRxiv. 2025 Jul 27. Huang C, Mathur A, Chang CH, Huang X, Chen HY, Davis ZB, O'Dell K, Shuman EA, Kung RW, Rogers GL, Cannon PM. PMID: 40777290; PMCID: PMC12330693.
      View in: PubMed   Mentions:
    3. International Call for a 10-Year Moratorium on Heritable Human Genome Editing: A multi-stakeholder initiative to ensure safe and responsible use of genetic technologies May 2025. Cytotherapy. 2025 Aug; 27(8):885-887. Barrett D, Cannon P, Forte M, Hunt T, Jang Q, Smith D. PMID: 40493001.
      View in: PubMed   Mentions:    Fields:    
    4. Correction: Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications. Gene Ther. 2024 Sep; 31(9-10):527. Bougioukli S, Chateau M, Morales H, Vakhshori V, Sugiyama O, Oakes D, Longjohn D, Cannon P, Lieberman JR. PMID: 39090205.
      View in: PubMed   Mentions: 1     Fields:    
    5. Reprogramming human B cells with custom heavy-chain antibodies. Nat Biomed Eng. 2024 Dec; 8(12):1700-1714. Rogers GL, Huang C, Mathur A, Huang X, Chen HY, Stanten K, Morales H, Chang CH, Kezirian EJ, Cannon PM. PMID: 39039240.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    6. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides. J Virol. 2023 08 31; 97(8):e0068423. Llewellyn GN, Chen HY, Rogers GL, Huang X, Sell PJ, Henley JE, Cannon PM. PMID: 37555663; PMCID: PMC10506483.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    7. Reprogramming human B cells with custom heavy chain antibodies. Res Sq. 2023 Jul 17. Rogers GL, Huang C, Mathur A, Huang X, Chen HY, Stanten K, Morales H, Chang CH, Kezirian EJ, Cannon PM. PMID: 37503066; PMCID: PMC10371167.
      View in: PubMed   Mentions:
    8. Reprogramming human B cells with custom heavy chain antibodies. bioRxiv. 2023 Jun 30. Rogers GL, Huang C, Mathur A, Huang X, Chen HY, Stanten K, Morales H, Chang CH, Kezirian EJ, Cannon PM. PMID: 37425794; PMCID: PMC10327003.
      View in: PubMed   Mentions:
    9. SARS-CoV-2 Enters Human Leydig Cells and Affects Testosterone Production In Vitro. Cells. 2023 04 20; 12(8). Li L, Sottas CM, Chen HY, Li Y, Cui H, Villano JS, Mankowski JL, Cannon PM, Papadopoulos V. PMID: 37190107; PMCID: PMC10136776.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    10. Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. Nat Commun. 2022 12 05; 13(1):7496. Krohn L, Heilbron K, Blauwendraat C, Reynolds RH, Yu E, Senkevich K, Rudakou U, Estiar MA, Gustavsson EK, Brolin K, Ruskey JA, Freeman K, Asayesh F, Chia R, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Gigli GL, Valente M, Janes F, Bernardini A, Högl B, Stefani A, Ibrahim A, Šonka K, Kemlink D, Oertel W, Janzen A, Plazzi G, Biscarini F, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Döring F, Cochen De Cock V, Monaca CC, Heidbreder A, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF, 23andMe Research Team, Scholz SW, Ryten M, Bandres-Ciga S, Noyce A, Cannon P, Pihlstrøm L, Nalls MA, Singleton AB, Rouleau GA, Postuma RB, Gan-Or Z. PMID: 36470867; PMCID: PMC9722930.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    11. Hospital re-admission after critical care survival: a systematic review and meta-analysis. Anaesthesia. 2022 04; 77(4):475-485. McPeake J, Bateson M, Christie F, Robinson C, Cannon P, Mikkelsen M, Iwashyna TJ, Leyland AH, Shaw M, Quasim T. PMID: 34967011.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    12. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med. 2021 12; 27(12):2085-2098. Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR, International AIDS Society (IAS) Global Scientific Strategy working group. PMID: 34848888.
      View in: PubMed   Mentions: 171     Fields:    Translation:Humans
    13. Knockdown of Astrocytic Monocarboxylate Transporter 4 in the Motor Cortex Leads to Loss of Dendritic Spines and a Deficit in Motor Learning. Mol Neurobiol. 2022 Feb; 59(2):1002-1017. Lundquist AJ, Llewellyn GN, Kishi SH, Jakowec NA, Cannon PM, Petzinger GM, Jakowec MW. PMID: 34822124.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    14. The genome-editing decade. Mol Ther. 2021 11 03; 29(11):3093-3094. Cannon PM, Kiem HP. PMID: 34699779; PMCID: PMC8571477.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    15. Genome edited B cells: a new frontier in immune cell therapies. Mol Ther. 2021 11 03; 29(11):3192-3204. Rogers GL, Cannon PM. PMID: 34563675; PMCID: PMC8571172.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    16. Optimization of AAV6 transduction enhances site-specific genome editing of primary human lymphocytes. Mol Ther Methods Clin Dev. 2021 Dec 10; 23:198-209. Rogers GL, Huang C, Clark RDE, Seclén E, Chen HY, Cannon PM. PMID: 34703842; PMCID: PMC8517001.
      View in: PubMed   Mentions: 20  
    17. Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation. J Virol. 2021 10 27; 95(22):e0096621. Chen HY, Huang C, Tian L, Huang X, Zhang C, Llewellyn GN, Rogers GL, Andresen K, O'Gorman MRG, Chen YW, Cannon PM. PMID: 34495700; PMCID: PMC8549521.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    18. Characterizing the Genetic Architecture of Parkinson's Disease in Latinos. Ann Neurol. 2021 09; 90(3):353-365. Loesch DP, Horimoto ARVR, Heilbron K, Sarihan EI, Inca-Martinez M, Mason E, Cornejo-Olivas M, Torres L, Mazzetti P, Cosentino C, Sarapura-Castro E, Rivera-Valdivia A, Medina AC, Dieguez E, Raggio V, Lescano A, Tumas V, Borges V, Ferraz HB, Rieder CR, Schumacher-Schuh A, Santos-Lobato BL, Velez-Pardo C, Jimenez-Del-Rio M, Lopera F, Moreno S, Chana-Cuevas P, Fernandez W, Arboleda G, Arboleda H, Arboleda-Bustos CE, Yearout D, Zabetian CP, 23andMe Research Team, Cannon P, Thornton TA, O'Connor TD, Mata IF, Latin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD). PMID: 34227697; PMCID: PMC8457043.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    19. Author Correction: The effect of LRRK2 loss-of-function variants in humans. Nat Med. 2021 Feb; 27(2):355. Whiffin N, Armean IM, Kleinman A, Marshall JL, Minikel EV, Goodrich JK, Quaife NM, Cole JB, Wang Q, Karczewski KJ, Cummings BB, Francioli L, Laricchia K, Guan A, Alipanahi B, Morrison P, Baptista MAS, Merchant KM, Genome Aggregation Database Production Team, Genome Aggregation Database Consortium, Ware JS, Havulinna AS, Iliadou B, Lee JJ, Nadkarni GN, Whiteman C, 23andMe Research Team, Daly M, Esko T, Hultman C, Loos RJF, Milani L, Palotie A, Pato C, Pato M, Saleheen D, Sullivan PF, Alföldi J, Cannon P, MacArthur DG. PMID: 33483629; PMCID: PMC8095267.
      View in: PubMed   Mentions:    Fields:    
    20. Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development. Hum Gene Ther. 2021 01; 32(1-2):31-42. Cannon P, Asokan A, Czechowicz A, Hammond P, Kohn DB, Lieber A, Malik P, Marks P, Porteus M, Verhoeyen E, Weissman D, Weissman I, Kiem HP. PMID: 33427035; PMCID: PMC8917879.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    21. Investigating human eyelash hair follicle growth in situ and ex vivo: a pilot study. Br J Dermatol. 2021 03; 184(3):553-555. Platt CI, Laybourne J, Cannon P, Paus R. PMID: 33006146.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Timothy Ray Brown: The Serendipitous Hero of HIV Cure Research. AIDS Res Hum Retroviruses. 2020 11; 36(11):883-885. Hope TJ, Klatt NR, Sacha JB, Cannon PM. PMID: 33050710.
      View in: PubMed   Mentions:    Fields:    
    23. Rational Selection of CRISPR-Cas9 Guide RNAs for Homology-Directed Genome Editing. Mol Ther. 2021 Mar 03; 29(3):1057-1069. Tatiossian KJ, Clark RDE, Huang C, Thornton ME, Grubbs BH, Cannon PM. PMID: 33160457; PMCID: PMC7934447.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    24. Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications. Gene Ther. 2021 12; 28(12):729-739. Bougioukli S, Chateau M, Morales H, Vakhshori V, Sugiyama O, Oakes D, Longjohn D, Cannon P, Lieberman JR. PMID: 32807899.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    25. The effect of LRRK2 loss-of-function variants in humans. Nat Med. 2020 06; 26(6):869-877. Whiffin N, Armean IM, Kleinman A, Marshall JL, Minikel EV, Goodrich JK, Quaife NM, Cole JB, Wang Q, Karczewski KJ, Cummings BB, Francioli L, Laricchia K, Guan A, Alipanahi B, Morrison P, Baptista MAS, Merchant KM, Genome Aggregation Database Production Team, Genome Aggregation Database Consortium, Ware JS, Havulinna AS, Iliadou B, Lee JJ, Nadkarni GN, Whiteman C, 23andMe Research Team, Daly M, Esko T, Hultman C, Loos RJF, Milani L, Palotie A, Pato C, Pato M, Saleheen D, Sullivan PF, Alföldi J, Cannon P, MacArthur DG. PMID: 32461697; PMCID: PMC7303015.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    26. SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder. Neurobiol Aging. 2020 09; 93:142.e5-142.e7. Rudakou U, Futhey NC, Krohn L, Ruskey JA, Heilbron K, Cannon P, 23andMe Research Team, Alam A, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Toffoli M, Gigli GL, Valente M, Högl B, Stefani A, Holzknecht E, Sonka K, Kemlink D, Oertel W, Janzen A, Plazzi G, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Döring F, De Cock VC, Monaca CC, Heidbreder A, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF, Postuma RB, Rouleau GA, Gan-Or Z. PMID: 32409254.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Fine-Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Ann Neurol. 2020 04; 87(4):584-598. Krohn L, Wu RYJ, Heilbron K, Ruskey JA, Laurent SB, Blauwendraat C, Alam A, Arnulf I, Hu MTM, Dauvilliers Y, Högl B, Toft M, Bjørnarå KA, Stefani A, Holzknecht E, Monaca CC, Abril B, Plazzi G, Antelmi E, Ferini-Strambi L, Young P, Heidbreder A, Cochen De Cock V, Mollenhauer B, Sixel-Döring F, Trenkwalder C, Sonka K, Kemlink D, Figorilli M, Puligheddu M, Dijkstra F, Viaene M, Oertel W, Toffoli M, Gigli GL, Valente M, Gagnon JF, Nalls MA, Singleton AB, 23andMe Research Team, Desautels A, Montplaisir JY, Cannon P, Ross OA, Boeve BF, Dupré N, Fon EA, Postuma RB, Pihlstrøm L, Rouleau GA, Gan-Or Z. PMID: 31976583; PMCID: PMC8025046.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    28. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain. 2020 01 01; 143(1):234-248. Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-Ciga S, Tan M, Gibbs JR, Hernandez DG, Kumaran R, Langston R, Bonet-Ponce L, Alcalay RN, Hassin-Baer S, Greenbaum L, Iwaki H, Leonard HL, Grenn FP, Ruskey JA, Sabir M, Ahmed S, Makarious MB, Pihlstrøm L, Toft M, van Hilten JJ, Marinus J, Schulte C, Brockmann K, Sharma M, Siitonen A, Majamaa K, Eerola-Rautio J, Tienari PJ, 23andMe Research Team, Pantelyat A, Hillis AE, Dawson TM, Rosenthal LS, Albert MS, Resnick SM, Ferrucci L, Morris CM, Pletnikova O, Troncoso J, Grosset D, Lesage S, Corvol JC, Brice A, Noyce AJ, Masliah E, Wood N, Hardy J, Shulman LM, Jankovic J, Shulman JM, Heutink P, Gasser T, Cannon P, Scholz SW, Morris H, Cookson MR, Nalls MA, Gan-Or Z, Singleton AB. PMID: 31755958; PMCID: PMC6935749.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansCells
    29. Gene Editing Expands the Donor Pool for CCR5-Negative Stem Cell Transplants. Cell Stem Cell. 2019 12 05; 25(6):735-736. Cannon PM. PMID: 31809736.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    30. Reply to "Efficient Nuclease-free HR by Clade F AAV Requires High MOIs with High Quality Vectors". Mol Ther. 2019 12 04; 27(12):2061-2062. Rogers GL, Chen HY, Morales H, Cannon PM. PMID: 31735602; PMCID: PMC6904797.
      View in: PubMed   Mentions:    Fields:    Translation:Cells
    31. Return to Employment after Critical Illness and Its Association with Psychosocial Outcomes. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2019 10; 16(10):1304-1311. McPeake J, Mikkelsen ME, Quasim T, Hibbert E, Cannon P, Shaw M, Ankori J, Iwashyna TJ, Haines KJ. PMID: 31184500.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    32. Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break. Mol Ther. 2019 10 02; 27(10):1726-1736. Rogers GL, Chen HY, Morales H, Cannon PM. PMID: 31540849; PMCID: PMC6822228.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    33. Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells. J Virol. 2019 05 15; 93(10). Llewellyn GN, Seclén E, Wietgrefe S, Liu S, Chateau M, Pei H, Perkey K, Marsden MD, Hinkley SJ, Paschon DE, Holmes MC, Zack JA, Louie SG, Haase AT, Cannon PM. PMID: 30842333; PMCID: PMC6498059.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    34. Reprogramming the antigen specificity of B cells using genome-editing technologies. Elife. 2019 01 17; 8. Voss JE, Gonzalez-Martin A, Andrabi R, Fuller RP, Murrell B, McCoy LE, Porter K, Huang D, Li W, Sok D, Le K, Briney B, Chateau M, Rogers G, Hangartner L, Feeney AJ, Nemazee D, Cannon P, Burton DR. PMID: 30648968; PMCID: PMC6355199.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    35. Protect NIH's DNA advisory committee. Science. 2018 10 26; 362(6413):409-410. Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L. PMID: 30361364.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. J Neurovirol. 2018 04; 24(2):192-203. Llewellyn GN, Alvarez-Carbonell D, Chateau M, Karn J, Cannon PM. PMID: 29256041; PMCID: PMC5910454.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    37. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. Nat Biotechnol. 2018 01; 36(1):95-102. Canny MD, Moatti N, Wan LCK, Fradet-Turcotte A, Krasner D, Mateos-Gomez PA, Zimmermann M, Orthwein A, Juang YC, Zhang W, Noordermeer SM, Seclen E, Wilson MD, Vorobyov A, Munro M, Ernst A, Ng TF, Cho T, Cannon PM, Sidhu SS, Sicheri F, Durocher D. PMID: 29176614; PMCID: PMC5762392.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansAnimalsCells
    38. Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases. Hematol Oncol Clin North Am. 2017 10; 31(5):883-895. Rogers GL, Cannon PM. PMID: 28895854.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    39. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun. 2017 03 01; 8:14447. Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra AA, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle PA, Wollmann G, von Laer D, Drexler I, Rathbun J, Cannon PM, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang PA, Lang KS. PMID: 28248314; PMCID: PMC5337983.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    40. Clinical Applications of Genome Editing to HIV Cure. AIDS Patient Care STDS. 2016 12; 30(12):539-544. Wang CX, Cannon PM. PMID: 27854119; PMCID: PMC5144849.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    41. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev. 2016; 3:16067. DiGiusto DL, Cannon PM, Holmes MC, Li L, Rao A, Wang J, Lee G, Gregory PD, Kim KA, Hayward SB, Meyer K, Exline C, Lopez E, Henley J, Gonzalez N, Bedell V, Stan R, Zaia JA. PMID: 27900346; PMCID: PMC5102145.
      View in: PubMed   Mentions: 52  
    42. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016 08; 22(8):839-50. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F, International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J. PMID: 27400264; PMCID: PMC5322797.
      View in: PubMed   Mentions: 282     Fields:    Translation:Humans
    43. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 2016 07; 30(7):291-306. Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva DM, Cannon PM, Kast WM. PMID: 27410493; PMCID: PMC4948215.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    44. The clinical applications of genome editing in HIV. Blood. 2016 05 26; 127(21):2546-52. Wang CX, Cannon PM. PMID: 27053530; PMCID: PMC4882804.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    45. A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathog Immun. 2016; 1(1):154-164. Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC. PMID: 27668293; PMCID: PMC5033048.
      View in: PubMed   Mentions: 26  
    46. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol. 2015 Dec; 33(12):1256-1263. Wang J, Exline CM, DeClercq JJ, Llewellyn GN, Hayward SB, Li PW, Shivak DA, Surosky RT, Gregory PD, Holmes MC, Cannon PM. PMID: 26551060; PMCID: PMC4842001.
      View in: PubMed   Mentions: 172     Fields:    
    47. Determinants in HIV-2 Env and tetherin required for functional interaction. Retrovirology. 2015 Aug 07; 12:67. Exline CM, Yang SJ, Haworth KG, Rengarajan S, Lopez LA, Droniou ME, Seclen E, Cannon PM. PMID: 26248668; PMCID: PMC4528709.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    48. Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening. J Virol. 2015 Aug; 89(16):8428-43. Rathbun JY, Droniou ME, Damoiseaux R, Haworth KG, Henley JE, Exline CM, Choe H, Cannon PM. PMID: 26041296; PMCID: PMC4524252.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    49. Genome editing technologies: defining a path to clinic. Mol Ther. 2015 May; 23(5):796-806. Corrigan-Curay J, O'Reilly M, Kohn DB, Cannon PM, Bao G, Bushman FD, Carroll D, Cathomen T, Joung JK, Roth D, Sadelain M, Scharenberg AM, von Kalle C, Zhang F, Jambou R, Rosenthal E, Hassani M, Singh A, Porteus MH. PMID: 25943494; PMCID: PMC4427885.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    50. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015 Mar 05; 519(7541):87-91. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M. PMID: 25707797; PMCID: PMC4352131.
      View in: PubMed   Mentions: 188     Fields:    Translation:AnimalsCells
    51. HIV eradication--from Berlin to Boston. Nat Biotechnol. 2014 Apr; 32(4):315-6. Cannon PM, Kohn DB, Kiem HP. PMID: 24714473.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    52. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. J Infect Dis. 2013 Nov; 208 Suppl 2:S160-4. Hofer U, Henley JE, Exline CM, Mulhern O, Lopez E, Cannon PM. PMID: 24151324; PMCID: PMC3807977.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    53. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther. 2013 Jun; 21(6):1259-69. Li L, Krymskaya L, Wang J, Henley J, Rao A, Cao LF, Tran CA, Torres-Coronado M, Gardner A, Gonzalez N, Kim K, Liu PQ, Hofer U, Lopez E, Gregory PD, Liu Q, Holmes MC, Cannon PM, Zaia JA, DiGiusto DL. PMID: 23587921; PMCID: PMC3677314.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansAnimalsCells
    54. A systems biology starter kit for arenaviruses. Viruses. 2012 Dec; 4(12):3625-46. Droniou-Bonzom ME, Cannon PM. PMID: 23342371; PMCID: PMC3528283.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    55. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol. 2012 May; 86(10):5467-80. Lopez LA, Yang SJ, Exline CM, Rengarajan S, Haworth KG, Cannon PM. PMID: 22398279; PMCID: PMC3347301.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    56. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP. J Virol. 2011 Dec; 85(24):13457-62. Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Exline CM, Rathbun JY, Cannon PM. PMID: 21976641; PMCID: PMC3233171.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    57. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology. 2011 Sep 28; 8:78. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. PMID: 21955466; PMCID: PMC3192746.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    58. Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS. 2011 Jan; 6(1):74-9. Cannon P, June C. PMID: 21242897; PMCID: PMC3066441.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    59. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010 Aug; 28(8):839-47. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM. PMID: 20601939; PMCID: PMC3080757.
      View in: PubMed   Mentions: 374     Fields:    Translation:HumansAnimalsCells
    60. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology. 2010 Jun 07; 7:51. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. PMID: 20529266; PMCID: PMC2890665.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansCells
    61. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol. 2010 Jul; 84(14):7243-55. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. PMID: 20444895; PMCID: PMC2898217.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    62. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology. 2010 Feb 18; 7:13. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. PMID: 20167081; PMCID: PMC2831821.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    63. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors. Retrovirology. 2010 Jan 26; 7:4. Christodoulopoulos I, Droniou-Bonzom ME, Oldenburg JE, Cannon PM. PMID: 20102634; PMCID: PMC2831008.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    64. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu. J Virol. 2010 Mar; 84(6):2666-74. Lucas TM, Lyddon TD, Cannon PM, Johnson MC. PMID: 20042505; PMCID: PMC2826068.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    65. Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther. 2009 Dec; 20(12):1607-26. Sumiyoshi T, Holt NG, Hollis RP, Ge S, Cannon PM, Crooks GM, Kohn DB. PMID: 19689196; PMCID: PMC4094131.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    66. Investigation of clade B New World arenavirus tropism by using chimeric GP1 proteins. J Virol. 2010 Jan; 84(2):1176-82. Martin VK, Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Cannon PM. PMID: 19889757; PMCID: PMC2798354.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    67. Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors. Gene Ther. 2008 Aug; 15(15):1079-89. Kahl CA, Cannon PM, Oldenburg J, Tarantal AF, Kohn DB. PMID: 18385767.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    68. New world clade B arenaviruses can use transferrin receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1. J Virol. 2008 Jan; 82(2):938-48. Flanagan ML, Oldenburg J, Reignier T, Holt N, Hamilton GA, Martin VK, Cannon PM. PMID: 18003730; PMCID: PMC2224602.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    69. Receptor use by the Whitewater Arroyo virus glycoprotein. Virology. 2008 Feb 20; 371(2):439-46. Reignier T, Oldenburg J, Flanagan ML, Hamilton GA, Martin VK, Cannon PM. PMID: 17997467; PMCID: PMC2270610.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    70. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther. 2007 Sep; 18(9):849-60. Weber EL, Cannon PM. PMID: 17767401.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    71. Differences in tropism and pH dependence for glycoproteins from the Clade B1 arenaviruses: implications for receptor usage and pathogenicity. Virology. 2007 Jul 20; 364(1):132-9. Oldenburg J, Reignier T, Flanagan ML, Hamilton GA, Cannon PM. PMID: 17397892; PMCID: PMC2743526.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    72. Receptor use by pathogenic arenaviruses. Virology. 2006 Sep 15; 353(1):111-20. Reignier T, Oldenburg J, Noble B, Lamb E, Romanowski V, Buchmeier MJ, Cannon PM. PMID: 16797051.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    73. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol. 2006 Mar; 80(6):2924-32. Noble B, Abada P, Nunez-Iglesias J, Cannon PM. PMID: 16501101; PMCID: PMC1395462.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    74. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol. 2005 Mar; 79(6):3627-38. Abada P, Noble B, Cannon PM. PMID: 15731257; PMCID: PMC1075700.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    75. Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide. J Virol. 2003 Jan; 77(2):1281-91. Aguilar HC, Anderson WF, Cannon PM. PMID: 12502845; PMCID: PMC140788.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    76. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet. 2002 Dec; 32(4):670-5. Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, Barcova M, Cannon PM, Mazurek C, Woodley DT. PMID: 12426566.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    77. Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Res. 2002 Feb 26; 83(1-2):43-56. Lin AH, Cannon PM. PMID: 11864740.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    78. Vesicular stomatitis virus G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells. J Virol. 2001 Dec; 75(23):11747-54. Borok Z, Harboe-Schmidt JE, Brody SL, You Y, Zhou B, Li X, Cannon PM, Kim KJ, Crandall ED, Kasahara N. PMID: 11689655; PMCID: PMC114760.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    79. Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. Int J Mol Med. 2001 Oct; 8(4):335-43. Masood R, Gordon EM, Whitley MD, Wu BW, Cannon P, Evans L, Anderson WF, Gill P, Hall FL. PMID: 11562769.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    80. Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary. J Virol. 2001 Aug; 75(15):6989-98. Logg CR, Logg A, Tai CK, Cannon PM, Kasahara N. PMID: 11435579; PMCID: PMC114427.
      View in: PubMed   Mentions: 38     Fields:    Translation:AnimalsCells
    81. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. J Virol. 2001 May; 75(9):4129-38. Christodoulopoulos I, Cannon PM. PMID: 11287562; PMCID: PMC114158.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    82. Receptor-specific targeting mediated by the coexpression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein. Hum Gene Ther. 2001 Mar 01; 12(4):323-32. Lin AH, Kasahara N, Wu W, Stripecke R, Empig CL, Anderson WF, Cannon PM. PMID: 11242525.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    83. Identification of regions in the Moloney murine leukemia virus SU protein that tolerate the insertion of an integrin-binding peptide. Virology. 2000 Mar 30; 269(1):7-17. Wu BW, Lu J, Gallaher TK, Anderson WF, Cannon PM. PMID: 10725193.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    84. Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. Hum Gene Ther. 1999 Mar 01; 10(4):545-57. Benedict CA, Tun RY, Rubinstein DB, Guillaume T, Cannon PM, Anderson WF. PMID: 10094198.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    85. Role of variable regions A and B in receptor binding domain of amphotropic murine leukemia virus envelope protein. J Virol. 1998 Nov; 72(11):9101-8. Han JY, Zhao Y, Anderson WF, Cannon PM. PMID: 9765455; PMCID: PMC110327.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    86. Characterization of the proline-rich region of murine leukemia virus envelope protein. J Virol. 1998 Jul; 72(7):5383-91. Weimin Wu B, Cannon PM, Gordon EM, Hall FL, Anderson WF. PMID: 9620992; PMCID: PMC110165.
      View in: PubMed   Mentions: 36     Fields:    Translation:AnimalsCells
    87. Functional domains in the retroviral transmembrane protein. J Virol. 1998 Jul; 72(7):5392-8. Zhao Y, Zhu L, Benedict CA, Chen D, Anderson WF, Cannon PM. PMID: 9620993; PMCID: PMC110168.
      View in: PubMed   Mentions: 28     Fields:    Translation:AnimalsCells
    88. Mutational analysis of the fusion peptide of Moloney murine leukemia virus transmembrane protein p15E. J Virol. 1998 Feb; 72(2):1632-9. Zhu NL, Cannon PM, Chen D, Anderson WF. PMID: 9445069; PMCID: PMC124647.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    89. Identification of envelope protein residues required for the expanded host range of 10A1 murine leukemia virus. J Virol. 1997 Nov; 71(11):8103-8. Han JY, Cannon PM, Lai KM, Zhao Y, Eiden MV, Anderson WF. PMID: 9343159; PMCID: PMC192265.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    90. Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. J Virol. 1997 May; 71(5):3474-83. Cannon PM, Matthews S, Clark N, Byles ED, Iourin O, Hockley DJ, Kingsman SM, Kingsman AJ. PMID: 9094619; PMCID: PMC191494.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    91. Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein. J Virol. 1997 May; 71(5):3613-9. Januszeski MM, Cannon PM, Chen D, Rozenberg Y, Anderson WF. PMID: 9094634; PMCID: PMC191509.
      View in: PubMed   Mentions: 56     Fields:    Translation:AnimalsCells
    92. Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy. J Virol. 1996 Nov; 70(11):8234-40. Cannon PM, Kim N, Kingsman SM, Kingsman AJ. PMID: 8892960; PMCID: PMC190909.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    93. Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication. J Virol. 1996 Jan; 70(1):651-7. Cannon PM, Byles ED, Kingsman SM, Kingsman AJ. PMID: 8523588; PMCID: PMC189861.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    94. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995 Feb 25; 23(4):628-33. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. PMID: 7899083; PMCID: PMC306730.
      View in: PubMed   Mentions: 306     Fields:    Translation:HumansAnimalsCells
    95. Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues. J Virol. 1994 Aug; 68(8):4768-75. Cannon PM, Wilson W, Byles E, Kingsman SM, Kingsman AJ. PMID: 8035478; PMCID: PMC236416.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    96. Analysis of Tat function in human immunodeficiency virus type 1-infected low-level-expression cell lines U1 and ACH-2. J Virol. 1994 Mar; 68(3):1993-7. Cannon P, Kim SH, Ulich C, Kim S. PMID: 8107261; PMCID: PMC236665.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    97. Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences. J Virol. 1994 Jan; 68(1):25-33. Braddock M, Cannon P, Muckenthaler M, Kingsman AJ, Kingsman SM. PMID: 8254735; PMCID: PMC236260.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    98. Human immunodeficiency virus-1 infection of the human promyelocytic cell line HL-60: high frequency of low-level infection and effect of subsequent cell differentiation. Blood. 1993 Jan 15; 81(2):437-45. Cannon PM, Tenen DG, Feinberg MB, Shin HS, Kim S. PMID: 8422463.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    99. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc Natl Acad Sci U S A. 1992 Nov 01; 89(21):10527-31. Luo L, Li Y, Cannon PM, Kim S, Kang CY. PMID: 1438241; PMCID: PMC50372.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    Paula's Networks
    Concepts (451)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (36)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.